Cryovials Market worth $0.31 billion by 2031
The report "Cryovials Market by Material (Polypropylene, Polyethylene, Glass), Application (Biobanking, Clinical Diagnostics, Cell & Gene Therapy, Drug Discovery), End User (Hospitals, Academia, Pharma-biopharma Cos., Biobanks) - Global Forecast to 2031", is projected to grow from USD 0.24 billion in 2026 and to reach USD 0.31 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period.
Browse 200 market data Tables and 50 Figures spread through 250 Pages and in-depth TOC on "Cryovials Market by Material (Polypropylene, Polyethylene, Glass), Application (Biobanking, Clinical Diagnostics, Cell & Gene Therapy, Drug Discovery), End User (Hospitals, Academia, Pharma-biopharma Cos., Biobanks) - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/cryovials-market-31904528.html
The global cryovials market is projected to reach USD 0.31 billion by 2031, up from USD 0.24 billion in 2026, reflecting a 5.5% CAGR from 2026 to 2031. Market growth is primarily driven by the expanding role of hospital-based biobanking and cord blood/stem cell storage programs, rising volumes of clinical and molecular diagnostic testing, and the scale-up of cell and gene therapy manufacturing across healthcare institutions. Additionally, increasingly stringent regulatory mandates from bodies such as the FDA and EMA on cold-chain integrity, sterility, and sample traceability are fostering adoption of certified, GMP-grade cryovials in hospital and clinical laboratory settings. Furthermore, emerging economies offer significant growth potential due to expanding healthcare infrastructure, rising diagnostic testing volumes, and growing government investment in biomedical research. Together, these factors are creating a favorable environment for sustained market expansion in the coming years.
The glass segment holds the major share in the cryovials market in 2025
Based on material, the cryovials market is segmented into plastic (polypropylene, polyethylene, and polystyrene) and glass vials. The plastic segment held the largest share of the cryovials market in 2025. Glass cryovials accounted for a significant share of the cryovials market in 2025, primarily due to their growing use for the long-term preservation of sensitive biological samples in biopharmaceutical research, vaccine development, cell biology, and biobanking. Their excellent chemical resistance, thermal stability, transparency, and low interaction with stored samples make glass cryovials well suited for applications requiring high levels of sample integrity. The continued expansion of biobanking and advanced therapeutic research is further supporting demand for dependable glass-based cryogenic storage solutions.
A key trend driving the adoption of glass cryovials is the growing focus on sample integrity and contamination-free, long-term storage. Research institutions and biopharmaceutical companies increasingly use high-quality cryovials to store valuable cells, tissues, and other biological materials at ultra-low temperatures. In addition, the growing adoption of regenerative medicine, genomics, and cell-based research is creating demand for cryovials with improved sealing performance, durability, and compatibility with automated storage systems, supporting the continued relevance of glass cryovials in specialized research and clinical applications.
The cell and gene therapy segment accounted for a significant share of the cryovials market, by application, in 2025.
Based on application, the cryovials market is segmented into cryopreservation and biobanking, clinical and diagnostic sample storage, drug discovery and development, cell and gene therapy, and transport of biological samples. The cell and gene therapy segment is experiencing strong growth in the cryovials market, supported by the increasing development and commercialization of advanced therapies, including CAR-T cell therapies, stem cell treatments, gene-modified therapies, and regenerative medicine. These applications require secure, consistent cryogenic storage across sample collection, processing, manufacturing, transportation, and administration to preserve cell viability and therapeutic performance. This growing need for reliable cold-chain storage is driving demand for sterile, high-quality cryovials designed for cell and gene therapy workflows.
Another important growth trend is the rising demand for validated, traceable, and high-performance cryovials that meet the stringent requirements of advanced therapy manufacturing. As cell and gene therapies move from early-stage clinical research to commercial-scale production, manufacturers are placing greater emphasis on sample integrity, contamination control, temperature resistance, and secure closure systems. The integration of barcode-based identification and compatibility with automated cryogenic storage systems is further accelerating the adoption of advanced cryovial solutions in this rapidly expanding segment.
The academic & research institutes are expected to register the highest CAGR
By end user, the cryovials market is segmented into hospitals and diagnostic laboratories, biobanks, pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), and other end users. The academic and research segment is growing steadily in the cryovials market, supported by rising investments in life sciences, molecular biology, genomics, proteomics, cancer research, and personalized medicine. Universities, research institutions, and government laboratories are increasingly conducting studies that require long-term preservation of biological materials such as cells, tissues, DNA, RNA, and blood samples. This expanding research activity is driving demand for reliable cryogenic storage solutions that maintain sample quality and integrity over extended periods.
A major trend supporting growth in this segment is the increasing adoption of advanced, traceable, and automation-compatible cryovials. Research laboratories and academic biobanks are handling growing volumes of biological samples, driving greater demand for cryovials with 2D barcodes, secure closures, and formats compatible with automated storage systems. The growing emphasis on sample identification, inventory management, contamination control, and reproducibility in collaborative research is further encouraging laboratories to adopt high-performance cryovial solutions.
The Asia Pacific market is projected to register the fastest growth in the market during the forecast period
The Asia Pacific cryovials market is projected to grow the fastest from 2026 to 2031, driven by rapid advances in healthcare infrastructure, biotechnology, and academic research. Major industry players are expanding their manufacturing and cold-chain distribution capabilities across countries such as China, India, Japan, and South Korea to meet rising regional demand. Increasing government funding for biomedical research, rising healthcare expenditures, and the establishment of hospital-affiliated biobanking and cell therapy centers are further fueling market expansion. Additionally, the growing adoption of validated, certified cryovials in clinical diagnostic laboratories, coupled with a shift toward precision medicine and automation, is creating significant growth opportunities for global and regional players operating in the APAC cryovials market.
Prominent players in the cryovials market include Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), DWK Life Sciences GmbH (Germany), Avantor, Inc. (US), Eppendorf SE (Germany), SARSTEDT AG & Co. KG (Germany), Sumitomo Bakelite Co., Ltd. (Japan), Biologix Group Limited (China), and Brooks Automation, Inc. (US), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cryovials Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
